Our second objective was to examine whether isoform-specific depletion of HSPA1 or HSPA2 would have an effect on resistance of NSCLC cells to platinum derivatives, CDDP and carboplatin (CPT), or proteasome inhibitor, BTZ. This evidence concerns the gene HSPA1B and non-small cell lung carcinoma.